This volume gives an overview ofstate of the art technologies and future developments in the field ofpreclinical pharmaceutical research. A balanced mix of experts from academiaand industry give insight in selected new developments in the drug discoverypathway. The topics cover the different parts of the drug discovery process,starting with new developments in the target identification and validationarea. The lead generation part as a next step focuses on the requirements andtechnologies to identify new small molecules as lead compounds for furtheroptimization; in a second section the…mehr
This volume gives an overview ofstate of the art technologies and future developments in the field ofpreclinical pharmaceutical research. A balanced mix of experts from academiaand industry give insight in selected new developments in the drug discoverypathway. The topics cover the different parts of the drug discovery process,starting with new developments in the target identification and validationarea. The lead generation part as a next step focuses on the requirements andtechnologies to identify new small molecules as lead compounds for furtheroptimization; in a second section the technologies to identify biologics asleads are addressed. The final part focuses on the pharmacological models andtechnologies to characterize new compounds and the impact of biomarkers to facilitatethe transfer of drug candidates into the development phase.
Dr. Ulrich Nielsch, Bayer Pharma AG,Wuppertal, Germany Dr. Ulrike Fuhrmann, Bayer Pharma AG, Berlin, Germany Prof. Dr. Stefan Jaroch, Bayer Pharma AG, Berlin, Germany
Inhaltsangabe
Preface.-Part 1. Historical View.- Drug discovery in the past and today.Part 2. Target Discovery.- Emerging target families:intractable targets. In vivo target validation especially for biologicaltargets. HR RNAi/High Content analysis.- Part 3. Lead generation and Optimization.- Sources for leads: natural products,libraries. Screening: assays, readout, technology. Impact of structuralbiology, fragment based screening/Virtual screening. Predictive in silico toolsof compound properties. High throughput synthesis. New compound classes:Protein-Protein Interaction. Sources for biological leads/Screening ofbiologicals.- Part 4. Test systems forEfficacy and Safety.- In vitro/ Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impactof biomarkers/personalized medicine. Simulating in vivo drug effects.
Preface.- Part 1. Historical View.- Drug discovery in the past and today.Part 2. Target Discovery.- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis.- Part 3. Lead generation and Optimization.- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals.- Part 4. Test systems for Efficacy and Safety.- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.
Preface.-Part 1. Historical View.- Drug discovery in the past and today.Part 2. Target Discovery.- Emerging target families:intractable targets. In vivo target validation especially for biologicaltargets. HR RNAi/High Content analysis.- Part 3. Lead generation and Optimization.- Sources for leads: natural products,libraries. Screening: assays, readout, technology. Impact of structuralbiology, fragment based screening/Virtual screening. Predictive in silico toolsof compound properties. High throughput synthesis. New compound classes:Protein-Protein Interaction. Sources for biological leads/Screening ofbiologicals.- Part 4. Test systems forEfficacy and Safety.- In vitro/ Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impactof biomarkers/personalized medicine. Simulating in vivo drug effects.
Preface.- Part 1. Historical View.- Drug discovery in the past and today.Part 2. Target Discovery.- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis.- Part 3. Lead generation and Optimization.- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals.- Part 4. Test systems for Efficacy and Safety.- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
